Botulism Market

SKU: DMOT1705 | Last Updated On: Jan 16 2023 | Available Formats

> Botulism Market Expected to reach a high CAGR of 7.5% By 2023-2030:

Botulism Market is segmented by By Toxin type (Type A, Type B, Type C, Type D, Type E, Type, F, Type G, Type H), By Botulism Type (Foodborne Botulism, Wound Botulism, Infant Botulism, Others (Adult intestinal colonization, Iatrogenic botulism)), By Treatment Type (Antitoxin, Antibiotics, Breathing assistance, Cathartics, Others), By End User (Hospital Pharmacies, Clinics, Retail pharmacies, Others), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) – Share, Size, Outlook, and Opportunity Analysis, 2023-2030.

[150 Pages Report] The Botulism Market is expected to grow at a CAGR of 7.5% during the forecasting period (2023-2030). Botulism is a severe form of food poisoning induced by eating tainted food. Clostridium botulinum is a spore-forming anaerobic bacterium that may grow in food-producing toxins. Botulinum antitoxin is generated from horse serum and has various side effects, including serum sickness, anaphylaxis, and the possibility of life-long sensitivity to equine proteins. Botulism inhibits nerve activity and, if left untreated for an extended time, can result in significant consequences such as death and paralysis. Vomiting, nausea, constipation, and double vision are some of the most prevalent symptoms of this illness. Botulism is most efficiently established clinically by finding botulinal toxin in the patient's blood, feces, or vomitus.

Botulism Market - Strategic Insights

Metrics

Details

Market CAGR

7.5%

Segments Covered

By Toxin type, By Botulism Type, By Treatment Type, By Distribution Channel and By Region

Report Insights Covered

Competitive Landscape Analysis, Company Profile Analysis, Market Size, Share, Growth, Demand, Recent Developments, Mergers and acquisitions, New Product Launches, Growth Strategies, Revenue Analysis, and Other key insights.

Fastest Growing Region

Asia Pacific

Largest Market Share 

North America

To Get a Free Sample Click here

Market Dynamics

Botulism market is primarily driven by the increase in food poisoning, availability of efficient botulism solutions, and favorable reimbursement policies.

Approvals and product launches by the market key players are expected to drive market growth.

Sihuan Pharmaceutical Holding Group Ltd. has gained approval to market its botulinum toxin product Letybo50U in February 2021. (Type A botulinum toxin for injection). Also, Maypharm plans to launch METOX, a novel botulinum toxin, in January 2021. It is an effective treatment for moderate to severe wrinkles induced by vigorous daily face motions. In addition, Huon's Global launched Liztox, a novel botulinum toxin product, in January 2019. Liztox completed multiple clinical trials for the product the same year and got permission from the Ministry of Food and Drug Safety. Thus, from the above statements, the market is expected to drive market growth.

Restraint:

However, high-cost investments required for the treatment, strict government regulations, and the wrong diagnosis are expected to restrain the market's growth for botulism. For instance, an Arizona company got shut down after four people got paralyzed when injected with botulin toxins that were not approved for human use.

Industry Analysis

The botulism market provides in-depth analysis of the market based on various industry factors such as porter five forces, supply chain, pricing analysis etc.

Segment Analysis

Antitoxins segment is expected to hold the largest market share in botulism market.

The antitoxins segment accounted for the largest market share in 2021. The segment is beneficial because of antitoxins, the main treatment for botulism. It interferes with the toxin in your bloodstream. This medication can often help stop symptoms from getting worse. For instance, BAT [Botulism Antitoxin Heptavalent (A, B, C, D, E, F, G) – (Equine)] is a mixture of immune globulin fragments indicated for the treatment of symptomatic botulism following documented or suspected exposure to botulinum neurotoxin serotypes A, B, C, D, E, F, or G in adults and pediatric patients. Therefore, it has increased the demand for antitoxins worldwide. Thus, from the above statements, the market segment accounted for the largest market share in the forecast period.

Geographical Analysis

North American region holds the largest market share in the global botulism market

North America accounted for the largest market share in 2021. The increasing prevalence of clostridium botulinum diseases, an increase in health awareness and the availability of advanced treatment procedures in the region are the factors the market is driven in the forecast period. For instance, according to the Centers for Disease Control and Prevention, an average of 145 cases are reported annually in the United States. Approximately 15% are foodborne, 65% are baby botulism, and 20% are wound. Therefore, it has increased the adoption of antitoxin drugs in the region. Thus, from the above statements, the North American region accounted for the largest market share in the forecast period.

Competitive Landscape

Major key players in the botulism market are Allergan Inc., Emergent BioSolutions Inc., Galderma S. A, Ipsen Technologies Pvt. Ltd, Valeant Pharmaceuticals Inc., AlphaVax Inc., Merz Pharma GmbH, Revance Therapeutics Inc., Microbiotix Inc., and XOMA Corporation.

Emergent BioSolutions Inc:

Overview:

Emergent BioSolutions Inc is a life sciences firm that develops products to address medical needs and public health issues (PHTs). Its solutions prevent PHTs such as chemical, biological, radiological, nuclear, and explosives (CBRNE), infectious illnesses, travel health, emerging health crises, and acute/emergency care. Its products include vaccines, medicines, drug-device combinations, and contract development and manufacturing services. Emergent's pipeline candidates are designed to combat dengue fever and other influenza illnesses. It also provides specialized goods to governments and businesses. The corporation sells its products through commercial sales forces and third-party distributors in the United States and Canada.

­Product Portfolio:

BAT [Botulism Antitoxin Heptavalent (A, B, C, D, E, F, G) – (Equine)] is a mixture of immune globulin fragments indicated for the treatment of symptomatic botulism following documented or suspected exposure to botulinum neurotoxin serotypes A, B, C, D, E, F, or G in adults and pediatric patients.

The global botulism market report would provide an access to an approx. 45+market data table, 40+figures and 180pages.

Trending Topics

Botulinum Toxin Market

Metabolism Drugs Market

Did not find what you were looking for?Every 7 out of 10 customers request tailored reports. Get yours today!
We collate your requirements.
Our global research team is put into action.
We deliver, and make sure your endeavour is a success!

Buy This Report

20% Discount Applied*



Note*: For "Bundle/Bulk" Subscription of Reports,
please contact: [email protected]

Get your free sample proposal with a single click!

linkedinpinterest